secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001171843-25-007188
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical regains exclusive Canadian distribution rights for TULSA-PRO from Knight Therapeutics
--------------------------------------------------------------------------------

- One-time cash payment of CDN$90,000 (US$64,000) and 5% royalty on Canadian net sales for 15 years.
- Only one Canadian site (Sunnybrook Health Sciences Centre) currently offers the TULSA Procedure; >100 procedures performed there.
- Plans to use CAPTAIN trial results (comparing TULSA vs robotic prostatectomy) for provincial insurance coverage applications starting 2026.
- Regained rights allow Profound to deploy its own direct North American sales team; interim concierge service model for new Canadian sites.
- Knight's CEO notes strategic fit: Knight focuses on pharma, while Profound is better suited to commercialize this complex medical device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325007188/0001171843-25-007188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325007188/f8k_111125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer